Showing 161-170 of 792 results for "".
Investigational Oral Treatments for Psoriasis: A Review of Phase 2 and 3 Trials
https://practicaldermatology.com/topics/psoriasis/investigational-oral-treatments-for-psoriasis-a-review-of-phase-2-and-3-trials/23318/Although biologic medications have proven to be highly effective in the treatment of psoriasis, there remains a need for oral medications that offer similar success rates. Here’s a look in the pipeline.Rediscovering Topical Antifungal Therapy for Onychomycosis
https://practicaldermatology.com/topics/hair-nails/rediscovering-topical-antifungal-therapy-for-onychomycosis/22974/A number of potential topical therapies for onychomycosis have failed clinical investigation. Do we at last have a viable alternative to oral treatment options?Beware of Your CPA's Advice on Asset Protection
https://practicaldermatology.com/topics/practice-management/beware-of-your-cpas-advice-on-asset-protection/21234/The advice you get may be inaccurate.Biologics for Psoriasis: A Status Update
https://practicaldermatology.com/topics/psoriasis/biologics-for-psoriasis-a-status-update/23006/The field has grown substantially from the early 2000s to include now a dozen innovator systemic agents, a host of biosimilars, and soon JAK Inhibitors.New In My Practice: Cosmeceuticals
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/new-in-my-practice-cosmeceuticals-4/24019/DefenAge 360-Rejuvenation Nail Root SerumA Long View: Conceptions of Atopic Dermatitis Through the Ages
https://practicaldermatology.com/topics/general-topics/a-long-view-conceptions-of-atopic-dermatitis-through-the-ages/21261/The Mind-Skin Connection: Psoriasis and Psychological Comorbidities
https://practicaldermatology.com/issues/supplements/the-mind-skin-connection-psoriasis-and-psychological-comorbidities/20833/Optimizing Dermatology Office Visits With Children and Families
https://practicaldermatology.com/topics/practice-management/optimizing-dermatology-office-visits-with-children-and-families/23897/Different ages call for different approaches when seeing pediatric patients.DermWireTV: Zoryve Approved; New SDPA President; Project Determi-Nation; Stelara for Pediatric PsA
https://practicaldermatology.com/topics/psoriasis/dermwiretv-zoryve-approved-new-sdpa-president-project-determi-nation-stelara-for-pediatric-psa/20115/FDA has approved Zoryve from Arcutis Biotherapeutics for the treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age or older. The novel formulation of roflumilast cream 0.3% is indicated for once-daily application. Stelara (ustekinumab) from Janssen is now approveThe State of Prevention in Atopic Dermatitis
https://practicaldermatology.com/topics/atopic-dermatitis/the-state-of-prevention-in-atopic-dermatitis/23183/